HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis.

Abstract
Osteoporosis is a major public health problem. Oral bisphosphonates are effective for reducing the risk of osteoporotic fractures and are an important treatment option for patients at risk for this condition. Osteonecrosis of the jaw (ONJ) is uncommon among cancer patients who are receiving high-dose intravenous bisphosphonates and rarely is seen among patients who are taking oral bisphosphonates for osteoporosis. Dentists play an important role in discussing the implications of the overall dental and medical treatment plans with both patients and physicians. The low risk of ONJ with oral bisphosphonates should be balanced against the benefits of osteoporosis therapy.
AuthorsMarjorie Jeffcoat, Nelson B Watts
JournalGeneral dentistry (Gen Dent) 2008 Jan-Feb Vol. 56 Issue 1 Pg. 96-102; quiz 103-4, 111-2 ISSN: 0363-6771 [Print] United States
PMID18254568 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Diphosphonates
Topics
  • Administration, Oral
  • Cost of Illness
  • Cost-Benefit Analysis
  • Diphosphonates (adverse effects, therapeutic use)
  • Humans
  • Jaw Diseases (chemically induced)
  • Osteonecrosis (chemically induced)
  • Osteoporosis (drug therapy)
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: